A Multicenter Phase I/II Trial of Abiraterone Acetate + BEZ235 in Metastatic, Castration-Resistant Prostate Cancer
Status:
Terminated
Trial end date:
2016-08-29
Target enrollment:
Participant gender:
Summary
There will be two parts to this clinical research study. The purpose of each part is:
- Phase 1: This part of the study will determine what dose of BEZ235 is safe to give with
a standard dose of abiraterone acetate and prednisone by administering different doses
of BEZ235. This will help to find out what effects, good and/or bad, this combination
has on CRPC.
- Phase 2: This part of the study will measure the treatment effect of the combination of
BEZ235 and abiraterone acetate/prednisone on CRPC.